<DOC>
	<DOC>NCT02953730</DOC>
	<brief_summary>The purpose of the trail is to study the pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor（PEG-rhG-CSF） in Children and Adolescents</brief_summary>
	<brief_title>The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>1. Age≤18 years old, gender no limited. 2. Patients with acute lymphoblastic leukemia diagnosed by bone marrow pathology or cytology. 3. Plan to receive CAM (cyclophosphamide,cytarabine,6MP)chemotherapy regimen. 4. Previously not received radiotherapy. 5. Karnofsky Performance Scores ( KPS)≥60. 6. The expected survival time was ＞3 months. 7. Neutropenia or agranulocytosis, no bleeding tendency. 8. No significant cardiac dysfunction or metabolic disease. 9. TBIL(total bilirubin ), ALT（alanine aminotransferase）,AST（glutamicoxalacetic transaminase） ＜ 2.5×ULN（upper limit of normal）. 10. BUN（blood urine nitrogen），Cr（creatinine），UA（uric acid）＜1.5×ULN. 11. Written informed consent are acquired. 1. With a history of systemic radiotherapy. 2. Infection difficult to control, the body temperature ≥ 38℃. 3. Other situation that investigators consider as contraindication for this study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>